Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?”

Samankaltaisia teoksia

• Reply to: Do interleukin 17 inhibitors increase risk of respiratory tract infections?
  Tekijä: Blauvelt, Andrew, et al.
  Julkaistu: (2020)
• In response to: “Reply to research letter”
  Tekijä: Wan, Marilyn T., et al.
  Julkaistu: (2020)
• The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
  Tekijä: Wan, Marilyn T., et al.
  Julkaistu: (2020)
• The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
  Tekijä: Syed, Maha N., et al.
  Julkaistu: (2020)
• Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic
  Tekijä: Syed, Maha N., et al.
  Julkaistu: (2021)